OR WAIT null SECS
March 30, 2023
Takeda plans to build a new facility in Osaka, Japan, for the manufacture of plasma-derived therapies.
Roche and Lilly will collaborate on the development of Roche Diagnostics’ Elecsys Amyloid Plasma Panel.
The Supreme Court heard oral arguments concerning the legitimacy of “genus clauses” in bio/pharma patents.
March 29, 2023
Narcan, from Emergent Solutions, will be the first naloxone product permitted for use without prescription by FDA.
March 27, 2023
PharmaBlock has opened a new R&D facility in Pennsylvania, expanding its capacity to deliver GMP projects.
Ingredion has completed two strategic investments in India with Amishi Drugs & Chemicals and Mannitab Pharma Specialties.
March 24, 2023
Moderna and Generation Bio have announced a strategic collaboration to develop non-viral genetic medicines.
Harm Reduction Therapeutics and Catalent have signed a commercial supply agreement for naloxone nasal spray to reverse opioid overdoses.
Curia is collaborating with Corning to advance biopharmaceutical continuous-flow development and manufacturing programs.
A new Interagency Working Group for Bayh-Dole will review the government’s authority to revoke licenses for medical products.